126 related articles for article (PubMed ID: 2561734)
41. Differential effects of transforming growth factor beta 1 on the growth of poorly and highly metastatic murine melanoma cells.
Mooradian DL; Purchio AF; Furcht LT
Cancer Res; 1990 Jan; 50(2):273-7. PubMed ID: 2295066
[TBL] [Abstract][Full Text] [Related]
42. Lack of expression of transforming growth factor-beta type II receptor associated with malignant progression in human salivary gland cell clones.
Azuma M; Yuki T; Tamatani T; Motegi K; Yoshida H; Sato M
Int J Cancer; 1996 Jun; 66(6):802-5. PubMed ID: 8647653
[TBL] [Abstract][Full Text] [Related]
43. Clonal heterogeneity of the sensitivity of human colon carcinoma cell lines to TGE beta isoforms.
Zhou GH; Sechrist GL; Brattain MG; Mulder KM
J Cell Physiol; 1995 Dec; 165(3):512-20. PubMed ID: 7593230
[TBL] [Abstract][Full Text] [Related]
44. Modulation of c-myc by transforming growth factor-beta in human colon carcinoma cells.
Mulder KM; Levine AE; Hernandez X; McKnight MK; Brattain DE; Brattain MG
Biochem Biophys Res Commun; 1988 Jan; 150(2):711-6. PubMed ID: 2893611
[TBL] [Abstract][Full Text] [Related]
45. Transplantation of human renal carcinomas into athymic mice.
Clayman RV; Figenshau RS; Bear A; Limas C
Cancer Res; 1985 Jun; 45(6):2650-3. PubMed ID: 3986801
[TBL] [Abstract][Full Text] [Related]
46. Transfection of the type II TGF-beta receptor into colon cancer cells increases receptor expression, inhibits cell growth, and reduces the malignant phenotype.
MacKay SL; Auffenberg T; Tannahill CL; Ksontini R; Josephs MD; Nowak M; Moldawer LL; Copeland EM
Ann Surg; 1998 Jun; 227(6):781-9. PubMed ID: 9637541
[TBL] [Abstract][Full Text] [Related]
47. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
[TBL] [Abstract][Full Text] [Related]
48. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
Okamoto M; Oyasu R
Cell Growth Differ; 1997 Aug; 8(8):921-6. PubMed ID: 9269901
[TBL] [Abstract][Full Text] [Related]
49. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.
Arteaga CL; Koli KM; Dugger TC; Clarke R
J Natl Cancer Inst; 1999 Jan; 91(1):46-53. PubMed ID: 9890169
[TBL] [Abstract][Full Text] [Related]
50. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
Song K; Cornelius SC; Danielpour D
Cancer Res; 2003 Aug; 63(15):4358-67. PubMed ID: 12907605
[TBL] [Abstract][Full Text] [Related]
51. IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells.
Rosendahl AH; Forsberg G
Kidney Int; 2006 Nov; 70(9):1584-90. PubMed ID: 16969385
[TBL] [Abstract][Full Text] [Related]
52. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
Yamamoto N; Imai J; Watanabe M; Hiroi N; Sugano S; Yoshino G
Horm Metab Res; 2006 Mar; 38(3):159-66. PubMed ID: 16673206
[TBL] [Abstract][Full Text] [Related]
53. Different signals mediate transforming growth factor-beta 1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells.
Franzén P; Ichijo H; Miyazono K
Exp Cell Res; 1993 Jul; 207(1):1-7. PubMed ID: 7686495
[TBL] [Abstract][Full Text] [Related]
54. In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer.
Hathorn RW; Tso CL; Kaboo R; Pang S; Figlin R; Sawyers C; deKernion JB; Belldegrun A
Cancer; 1994 Oct; 74(7):1904-11. PubMed ID: 7521786
[TBL] [Abstract][Full Text] [Related]
55. Isolation and characterization of a rat liver epithelial cell line resistant to the antiproliferative effects of transforming growth factor beta (type 1).
Chapekar MS; Huggett AC; Cheng CC; Hampton LL; Lin KH; Thorgeirsson SS
Cancer Res; 1990 Jun; 50(12):3600-4. PubMed ID: 2111209
[TBL] [Abstract][Full Text] [Related]
56. Presence of transforming growth factors in human breast cancer cells.
Salomon DS; Zwiebel JA; Bano M; Losonczy I; Fehnel P; Kidwell WR
Cancer Res; 1984 Sep; 44(9):4069-77. PubMed ID: 6331663
[TBL] [Abstract][Full Text] [Related]
57. Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination.
Perry K; Wong L; Liu V; Park I; Zhang Q; Rejen V; Huang X; Smith ND; Jovanovic B; Lonning S; Teicher BA; Lee C
Urology; 2008 Jul; 72(1):225-9. PubMed ID: 18295867
[TBL] [Abstract][Full Text] [Related]
58. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro.
Wilding G; Zugmeier G; Knabbe C; Flanders K; Gelmann E
Mol Cell Endocrinol; 1989 Mar; 62(1):79-87. PubMed ID: 2545487
[TBL] [Abstract][Full Text] [Related]
59. [Regulation of tumor metastasis and invasion by fibroblasts].
Nakajima M
Hum Cell; 1993 Mar; 6(1):7-14. PubMed ID: 8343451
[TBL] [Abstract][Full Text] [Related]
60. Transfection and expression of mutant p53 protein does not alter the in vivo or in vitro growth characteristics of the AA/C1 human adenoma derived cell line, including sensitivity to transforming growth factor-beta 1.
Williams AC; Browne SJ; Manning AM; Daffada P; Collard TJ; Paraskeva C
Oncogene; 1994 May; 9(5):1479-85. PubMed ID: 8152811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
